Stratus Versus Cirrus OCT in AMD
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00568191 |
Recruitment Status
: Unknown
Verified December 2007 by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery.
Recruitment status was: Recruiting
First Posted
: December 5, 2007
Last Update Posted
: December 5, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Age-Related Macular Degeneration Choroidal Neovascularization |
Study Type : | Observational |
Estimated Enrollment : | 100 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Reliability of Threshold Algorithm in Age-Related Macular Degeneration: Stratus Versus Cirrus OCT |
Study Start Date : | October 2007 |
Estimated Study Completion Date : | December 2007 |

Group/Cohort |
---|
1
retinal thickness program Stratus OCT software 4.0
|
2
retinal cube 200x200 program of Cirrus OCT
|
- Number of algorithm failures assessed by Stratus OCT versus Cirrus OCT in the horizontal central line [ Time Frame: only 1 examination ]
- Number of algorrithm failures in Stratus versus Cirrus OCT assessed in the whole scan [ Time Frame: 1 examination ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 55 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Age>55 years
- Age-related macular degeneration
Exclusion Criteria:
- Not consented patients

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00568191
Contact: Ilse Krebs, MD | +43171165 ext 94607 | Ilse.Krebs@wienkav.at |
Austria | |
Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery | Recruiting |
Vienna, Austria, A1030 | |
Contact: Ilse Krebs, MD +43171165 ext 4607 Ilse.Krebs@wienkav.at | |
Principal Investigator: Ilse Krebs, MD |
Principal Investigator: | Ilse Krebs | Ludwig Boltzmann Institute of Retinology and Biomicroscopic Lasersurgery |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Prof Susanne Binder, The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery |
ClinicalTrials.gov Identifier: | NCT00568191 History of Changes |
Other Study ID Numbers: |
EK 06-007-VK1 |
First Posted: | December 5, 2007 Key Record Dates |
Last Update Posted: | December 5, 2007 |
Last Verified: | December 2007 |
Keywords provided by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery:
Age-related macular degeneration choroidal neovascularization Stratus OCT Cirrus OCT |
Additional relevant MeSH terms:
Macular Degeneration Neovascularization, Pathologic Choroidal Neovascularization Retinal Degeneration Retinal Diseases |
Eye Diseases Metaplasia Pathologic Processes Choroid Diseases Uveal Diseases |